Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Mesothelioma EORTC Prognostic Index

The EORTC Prognostic Index identifies poor prognostic factors for patients with Malignant Pleural Mesothelioma.

Evidence-based context for fast calculator use

Purpose:
EORTC Prognostic Index predicts survival in malignant pleural mesothelioma to guide decisions on multimodal therapy versus supportive care.
Population:
patients undergoing thoracic oncology risk, staging, or nodule assessment
Factors:
White Blood Cell Count> 8.3 x 10⁹/L?, ECOG Performance Status > 0?, Histology, Gender, Diagnosis Certainty
Reference:
Curran D, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-152.
HomeMesothelioma EORTC Prognostic Index
Pin your most used calculators here by clicking the star in the dropdown.

Mesothelioma EORTC Prognostic Index

Clinical Context & Background

The EORTC Prognostic Index identifies poor prognostic factors for patients with Malignant Pleural Mesothelioma. It stratifies patients into low or high risk groups, which helps guide treatment decisions (e.g., aggressive multimodal therapy vs. supportive care).
Primary Source EvidenceCurran D, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-152.
Formula Logic
Score based on WBC, Performance Status, Histology, Gender, and Diagnosis Certainty.

Reference Data

Risk GroupScoreMedian Survival (Historical)
Low Risk0 - 1.2710.8 months
High Risk> 1.275.5 months

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Mesothelioma EORTC Prognostic Index when eORTC Prognostic Index predicts survival in malignant pleural mesothelioma to guide decisions on multimodal therapy versus supportive care.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm whether the clinical question is screening eligibility, nodule malignancy, staging, or treatment prognosis and move to the corresponding thoracic pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Lung screening, nodule probability, radiology classification, and cancer staging tools answer different questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing thoracic oncology risk, staging, or nodule assessment

How to apply this result

For a representative case, verify White Blood Cell Count> 8.3 x 10⁹/L?, ECOG Performance Status > 0?, Histology, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Lung & Thoracic Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Small Cell Lung Cancer Staging (VALSG)Solitary Pulmonary Nodule Malignancy Risk (Mayo)Herder Model (Pulmonary Nodule)

Frequently Asked Questions

When should Mesothelioma EORTC Prognostic Index be used?

Use it for patients undergoing thoracic oncology risk, staging, or nodule assessment when all required inputs and the intended clinical setting are confirmed.

Can Mesothelioma EORTC Prognostic Index determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.